4/A: Processa CEO Amends Stock Ownership Disclosure

Processa Pharmaceuticals CEO George Ng filed an amended Form 4 to correct previously reported beneficial ownership of common stock and warrants.

Summary

• George K. Ng, Chief Executive Officer, Director, and 10% Owner of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4.
• The amendment was filed to retract a prior Form 4 that was submitted in error on July 28, 2025.
• The filing clarifies Ng's beneficial ownership of 107,200 shares of common stock.
• Of the common stock, 87,200 shares are held indirectly through George Ng IRRA FBO: George Ng, and 20,000 shares are held indirectly through the Ng Cha Family Trust.
• Ng also beneficially owns 130,800 warrants, all held indirectly through George Ng IRRA FBO: George Ng.
• These warrants have an exercise price of $0.65, become exercisable on January 29, 2025, and expire on January 29, 2030.

Sentiment

Score: 5

Explanation: The filing is an administrative correction of a previously erroneous beneficial ownership report, indicating a neutral impact on the company's operational or financial performance.

Positives

• Ensures accurate and transparent disclosure of beneficial ownership by a key executive, enhancing corporate governance.

Negatives

• An initial Form 4 was filed in error, requiring an amendment, which indicates a potential administrative oversight.

Risks

• Potential for minor regulatory scrutiny due to the initial erroneous filing, although promptly corrected by this amendment.

Future Outlook

Warrants held by George Ng become exercisable on January 29, 2025, and are set to expire on January 29, 2030.

Management Comments

• The amendment was filed to retract the prior Form 4, which was filed in error.

Industry Context

This filing is a standard compliance disclosure regarding insider ownership, reflecting transparency requirements within the pharmaceutical industry for publicly traded companies.

Related Party Transactions

• Indirect beneficial ownership of 20,000 common shares through the Ng Cha Family Trust.

Stakeholder Impact

• Shareholders: Provides accurate and updated information on insider ownership, contributing to market transparency and informed investment decisions.

Next Steps

• George Ng may choose to exercise the warrants once they become exercisable on January 29, 2025.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, George Ng, CEO, Director, beneficial ownership, Form 4, SEC filing, common stock, warrants, insider ownership